Sept. 20, 2010: Transcatheter heart valve company CardiAQ Valve Technologies (“CVT”), announced today that its Phase 1 porcine model study has clearly demonstrated the capability of its proprietary transcatheter delivery system to successfully and repeatedly deliver a mitral valve implant. [click here for more info]…

June 23, 2010: Santaris Pharma A/S and miRagen Therapeutics, Inc., form a strategic alliance to develop microRNA-targeted medicines for the treatment of cardiovascular disease. [click here for more info]...

June 1, 2010: Transcatheter heart valve company CardiAQ Valve Technologies (“CVT”), announced today that it has established operations in Irvine, Calif. [click here for more info]…

May 20, 2010: Transcatheter heart valve company CardiAQ Valve Technologies (“CVT”), announced today that its proprietary transcatheter delivery system was employed to successfully deliver a mitral valve implant in the porcine model. [click here for more info]…

January 12, 2010: Transcatheter heart valve company CardiAQ Valve Technologies (CVT), announced today that it has closed a $6.5 million ‘Series A’ funding led by a group of private investors with proven expertise in the transcatheter heart valve space. [click here for more info]…